2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.11B.03 Body Mass Index and Genetic Association in Durable Responders to Immunotherapy in Metastatic Non-Small Cell Lung Cancer

EP.11B.03 Body Mass Index and Genetic Association in Durable Responders to Immunotherapy in Metastatic Non-Small Cell Lung Cancer

Back to course

Pdf Summary

This study explores the association between Body Mass Index (BMI) and genetic factors in predicting the durability of responses to immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC). Immunotherapy has significantly improved outcomes for many NSCLC patients, but genetic characteristics in relation to different BMI categories and their impact on immunotherapy responses are not well understood.<br /><br />The research included NSCLC patients who were administered immune checkpoint inhibitors (ICI) between January 2017 and December 2021 at Montefiore Medical Center. Participants were classified into two groups: durable responders (DR) who remained on treatment for 18 months or longer, and non-durable responders (NDR) with treatment duration under 18 months.<br /><br />Key findings from this study indicate that a better Eastern Cooperative Oncology Group (ECOG) performance status and a higher BMI (overweight or obese) were linked to more durable responses to ICIs. Specifically, in the DR group, there was a notably lower incidence of STK11 mutations than in the NDR group. Additionally, among patients with BMI ≥ 25, SMARCA4 mutations were observed more frequently compared to those with BMI < 25.<br /><br />The research underscores the importance of BMI and specific genetic mutations in the context of immunotherapy responsiveness, suggesting that these factors could be predictive of longer treatment effectiveness. The study suggests further prospective research to deepen understanding of the genetic characteristics influencing long-term response to immunotherapy in NSCLC.<br /><br />Overall, this investigation provides insights into how physical and genetic factors potentially influence the outcomes of immune-based cancer therapies, presenting avenues for personalized treatment strategies in metastatic NSCLC.

Asset Subtitle

Shuai Wang

Meta Tag

Speaker Shuai Wang

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

BMI

genetic factors

immunotherapy

NSCLC

immune checkpoint inhibitors

durable responders

STK11 mutations

SMARCA4 mutations

ECOG performance status

personalized treatment